The bidding war goes on to acquire Obagi Medical Products (NASDAQ: OMPI) and its dermatological product line, with the acquisitive Valeant Pharmaceuticals (BHC 7.85%) as the current top bidder at $24 per share. The ongoing bidding war has Obagi up another 10% today. Are we close to seeing a deal? In this video, Fool health-care analyst David Williamson tells investors how to play this buyout bidding race, both for current shareholders, and for those currently sitting on the sidelines.